Rhenman & Partners Asset Management AB Grows Position in Dianthus Therapeutics, Inc. $DNTH

Rhenman & Partners Asset Management AB boosted its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 37.1% in the third quarter, Holdings Channel.com reports. The institutional investor owned 173,627 shares of the company’s stock after acquiring an additional 47,000 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Dianthus Therapeutics were worth $6,832,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Patient Square Capital LP purchased a new position in shares of Dianthus Therapeutics during the third quarter valued at approximately $4,919,000. XTX Topco Ltd purchased a new stake in Dianthus Therapeutics in the second quarter worth approximately $503,000. Sio Capital Management LLC grew its position in Dianthus Therapeutics by 101.8% in the 2nd quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock worth $4,398,000 after purchasing an additional 119,073 shares during the period. Ensign Peak Advisors Inc purchased a new stake in Dianthus Therapeutics during the 2nd quarter valued at $2,504,000. Finally, Candriam S.C.A. raised its stake in Dianthus Therapeutics by 25.3% during the 3rd quarter. Candriam S.C.A. now owns 301,428 shares of the company’s stock valued at $11,861,000 after buying an additional 60,852 shares during the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Trading Up 6.1%

Shares of NASDAQ:DNTH opened at $65.20 on Friday. The stock has a 50 day moving average of $48.42 and a 200 day moving average of $40.65. The company has a market cap of $2.82 billion, a PE ratio of -18.74 and a beta of 1.56. Dianthus Therapeutics, Inc. has a 12-month low of $13.36 and a 12-month high of $65.50.

Analyst Upgrades and Downgrades

DNTH has been the subject of several research analyst reports. Truist Financial lifted their price objective on Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. HC Wainwright raised their target price on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Jefferies Financial Group boosted their price target on Dianthus Therapeutics from $66.00 to $81.00 and gave the company a “buy” rating in a research note on Monday, February 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Wednesday, January 21st. Finally, Wedbush increased their price objective on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 11th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $67.63.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.